诺瓦瓦克斯医药（NVAX）今日盘中股价大幅上涨17.96%，引起了市场的广泛关注。
消息面上，该公司公布的第一季度营收表现强劲，超出了华尔街分析师的普遍预期。根据报告，诺瓦瓦克斯第一季度营收达到1.395亿美元，远高于分析师平均预期的7830万美元，这主要得益于疫苗供应及授权协议带来的预付款和里程碑付款，有效抵消了市场需求疲软带来的压力。
此外，公司管理层表示正持续推进降本增效计划，目标是在未来几年内大幅削减研发及行政费用，并维持了2026年的调整后营收预测。这些积极的财务表现和成本控制措施增强了投资者对公司未来发展的信心，推动了股价的显著上涨。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.